thiosulfates has been researched along with Hepatoblastoma in 2 studies
Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.
thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.
Hepatoblastoma: A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomly assigned children older than 1 month and younger than 18 years of age who had standard-risk hepatoblastoma (≤3 involved liver sectors, no metastatic disease, and an alpha-fetoprotein level of >100 ng per milliliter) to receive cisplatin alone (at a dose of 80 mg per square meter of body-surface area, administered over a period of 6 hours) or cisplatin plus sodium thiosulfate (at a dose of 20 g per square meter, administered intravenously over a 15-minute period, 6 hours after the discontinuation of cisplatin) for four preoperative and two postoperative courses." | 9.27 | Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. ( Ansari, M; Brichard, B; Brock, PR; Brugières, L; Capra, M; Childs, M; Covezzoli, A; Czauderna, P; Dall'Igna, P; Hiyama, E; Laithier, V; Maibach, R; Mateos, ME; Morland, B; Neuwelt, EA; Perilongo, G; Rajput, K; Rangaswami, AA; Rechnitzer, C; Roebuck, D; Ronghe, M; Skeen, J; Sullivan, MJ; Veal, GJ, 2018) |
| "We randomly assigned children older than 1 month and younger than 18 years of age who had standard-risk hepatoblastoma (≤3 involved liver sectors, no metastatic disease, and an alpha-fetoprotein level of >100 ng per milliliter) to receive cisplatin alone (at a dose of 80 mg per square meter of body-surface area, administered over a period of 6 hours) or cisplatin plus sodium thiosulfate (at a dose of 20 g per square meter, administered intravenously over a 15-minute period, 6 hours after the discontinuation of cisplatin) for four preoperative and two postoperative courses." | 5.27 | Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. ( Ansari, M; Brichard, B; Brock, PR; Brugières, L; Capra, M; Childs, M; Covezzoli, A; Czauderna, P; Dall'Igna, P; Hiyama, E; Laithier, V; Maibach, R; Mateos, ME; Morland, B; Neuwelt, EA; Perilongo, G; Rajput, K; Rangaswami, AA; Rechnitzer, C; Roebuck, D; Ronghe, M; Skeen, J; Sullivan, MJ; Veal, GJ, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brock, PR | 1 |
| Maibach, R | 1 |
| Childs, M | 1 |
| Rajput, K | 1 |
| Roebuck, D | 1 |
| Sullivan, MJ | 2 |
| Laithier, V | 1 |
| Ronghe, M | 1 |
| Dall'Igna, P | 1 |
| Hiyama, E | 1 |
| Brichard, B | 1 |
| Skeen, J | 1 |
| Mateos, ME | 1 |
| Capra, M | 1 |
| Rangaswami, AA | 1 |
| Ansari, M | 1 |
| Rechnitzer, C | 1 |
| Veal, GJ | 1 |
| Covezzoli, A | 1 |
| Brugières, L | 1 |
| Perilongo, G | 1 |
| Czauderna, P | 1 |
| Morland, B | 1 |
| Neuwelt, EA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Incorporating a Randomized Assessment of Sodium Thiosulfate as Otoprotection for Children With Localized Disease, and Respons[NCT04478292] | Phase 3 | 330 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| A Multi-centre Open-label Randomised Phase III Trial of the Efficacy of Sodium Thiosulphate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma[NCT00652132] | Phase 3 | 116 participants (Actual) | Interventional | 2007-12-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thiosulfates and Hepatoblastoma
| Article | Year |
|---|---|
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll | 2018 |
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll | 2018 |
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll | 2018 |
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll | 2018 |
1 other study available for thiosulfates and Hepatoblastoma
| Article | Year |
|---|---|
Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.
Topics: Amifostine; Cisplatin; Clinical Trials as Topic; Hearing Loss; Hepatoblastoma; Humans; Infant; Inter | 2009 |